Macrogenics (MGNX) Other Operating Expenses (2021 - 2026)
Macrogenics (MGNX) posted quarterly Other Operating Expenses of $9.5 million for Q1 2026, up 76.48% year-over-year from $5.4 million in Q1 2025, and down 5.78% quarter-over-quarter from $10.1 million in Q4 2025.
Macrogenics (MGNX) Other Operating Expenses (2021 - 2026) Analysis & Trends
Macrogenics (MGNX) has reported Other Operating Expenses for 6 consecutive years, with $9.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Operating Expenses rose 76.48% year-over-year to $9.5 million; the TTM figure through Mar 2026 stood at $40.1 million (up 157.59% YoY), while the FY2025 annual figure was $36.0 million, up 192.78% from the prior year.
- Other Operating Expenses fell to $9.5 million in Q1 2026 per MGNX's latest filing, from $10.1 million in the prior quarter.
- Across five years, Other Operating Expenses topped out at $11.6 million in Q3 2025 and bottomed at $48000.0 in Q1 2022.
- Historically, Other Operating Expenses has averaged $4.3 million across 5 years, with a median of $3.1 million in 2022.
- Annual changes were most pronounced in 2022 — Other Operating Expenses jumped 10818.18% — and 2023, when it tumbled 90.9%.
- Macrogenics' Other Operating Expenses stood at $1.8 million in 2022, then sank by 90.9% to $163000.0 in 2023, then jumped by 3268.1% to $5.5 million in 2024, then jumped by 84.24% to $10.1 million in 2025, then slipped by 5.78% to $9.5 million in 2026.
- Business Quant data shows MGNX's Other Operating Expenses at $9.5 million in Q1 2026, $10.1 million in Q4 2025, and $11.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Macrogenics | 268.22 Mn | 201.71 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.53 Mn |
| Dec 31, 2025 | 10.12 Mn |
| Sep 30, 2025 | 11.59 Mn |
| Jun 30, 2025 | 8.91 Mn |
| Mar 31, 2025 | 5.40 Mn |
| Dec 31, 2024 | 5.49 Mn |
| Sep 30, 2024 | 1.87 Mn |
| Jun 30, 2024 | 2.82 Mn |
| Mar 31, 2024 | 2.12 Mn |
| Dec 31, 2023 | 163,000.00 |
| Sep 30, 2023 | 3.36 Mn |
| Jun 30, 2023 | 1.18 Mn |
| Mar 31, 2023 | 3.52 Mn |
| Dec 31, 2022 | 1.79 Mn |
| Sep 30, 2022 | 3.14 Mn |
| Jun 30, 2022 | 2.40 Mn |
| Mar 31, 2022 | 48,000.00 |
| Dec 31, 2021 | 947,000.00 |
| Sep 30, 2021 | 1.67 Mn |
| Jun 30, 2021 | 22,000.00 |